Radiopharm Theranostics (ASX:RAD) raise $5 million via the execution of a subscription agreement for a private placement of 133 million ordinary shares to Lantheus Holdings, according to a Friday Australian bourse filing.
After the placement, Lantheus' shareholding in the firm rose to 12.16%.
The placement was completed at an issue price of AU$0.06 apiece, and under Radiopharm's existing
placement capacity.
The radiopharmaceuticals firm will use the funds for the development of its clinical pipeline.
The placement replaces the six-month options that it issued in August 2024.
The firm's shares surged 58% in recent trade on Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。